Lakefront Biotherapeutics (LKFT) Income from Discontinued Operations (2020 - 2024)
Lakefront Biotherapeutics (LKFT) posted quarterly Income from Discontinued Operations of 85801752.05 for Q4 2024, down 65.04% year-on-year from 245456736.3 in Q1 2024, and down 65.04% on a QoQ basis from 245456736.3 in Q4 2023.
Lakefront Biotherapeutics (LKFT) Income from Discontinued Operations (2020 - 2024) Analysis & Trends
Lakefront Biotherapeutics (LKFT) has reported Income from Discontinued Operations for 4 consecutive years, with 85801752.05 the latest figure, recorded in Q4 2024.
- Quarterly Income from Discontinued Operations fell 65.04% year-over-year to 85801752.05 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was 356521073.17 (up 31.69% YoY) and the FY2024 annual result came in at 85801752.05, down 65.04% from the prior year.
- Income from Discontinued Operations slipped to 85801752.05 in Q4 2024 per LKFT's latest filing, from 245456736.3 in the prior quarter.
- Over the last five years, Income from Discontinued Operations for LKFT reached as high as 245456736.3 in Q4 2023 and fell as low as 1934522.26 in Q1 2020.
- A 4-year average of 64749598.03 and a median of 25262584.82 in 2021 frame the typical range for Income from Discontinued Operations.
- Annual changes were most pronounced in 2021 — Income from Discontinued Operations jumped 1205.88% — and 2024, when it sank 65.04%.
- Year by year, Income from Discontinued Operations stood at 4779407.94 in 2020, then surged by 428.57% to 25262584.82 in 2021, then soared by 871.62% to 245456736.3 in 2023, then plunged by 65.04% to 85801752.05 in 2024.
- According to Business Quant data, Income from Discontinued Operations over the past three periods registered 85801752.05, 245456736.3, and 25262584.82 for Q4 2024, Q4 2023, and Q3 2021 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Discontinued) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,102.16 Bn | 67,101.87 Bn | - | - |
| 2 | Nanobiotix | 1,913.50 Bn | 1,913.44 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 472.39 Bn | 467.60 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 122.08 Bn | 114.83 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.98 Bn | 61.22 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - | - |
| 8 | Argenx Se | 55.97 Bn | 50.78 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.47 Bn | 34.46 Bn | 959.66 Mn | - |
| 10 | Lakefront Biotherapeutics | 1.86 Bn | -1.54 Bn | 1.91 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 85.80 Mn |
| Dec 31, 2023 | 245.46 Mn |
| Sep 30, 2021 | 25.26 Mn |
| Mar 31, 2021 | 25.26 Mn |
| Sep 30, 2020 | 4.78 Mn |
| Mar 31, 2020 | 1.93 Mn |